FDA Approves HYDROCODONE BITARTRATE AND ACETAMINOPHEN — SpecGx LLC
SpecGx LLC announced Monday that its ANDA040409 application for hydrocodone bitartrate and acetaminophen tablets was granted final approval. This move expands generic competition into a high-volume therapeutic space, potentially placing downward pressure on pricing for the branded pain management market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed